CXCR5 / CD185 (Polyclonal), RPab

Summary and Explanation

CXCR5 antibody is highly expressed in primary and secondary follicles within gastric lymphomas. non-small cell lung cancer (NSCLC) tissues express CXCR5, which correlates with stage/grade of the disease. Higher CXCR5 expression and migration by NSCLC cells suggest a role in migration and metastasis of primary lung tumors in response to CXCL13. These findings indicate that differential expression patterns of CXCR5 and CXCL13 in two subtypes (squamous cell carcinoma and adenocarcinoma) of NSCLC are associated with differences in their prognosis and survival. It has been proposed that CXCR5/CXCL13, either alone or in combination, could be used as a prognostic biomarker for lung cancer. Other studies have shown that CXCR5 overexpression in breast cancer patients highly correlates with lymph node metastases, and elevated CXCR5 antibody expression may contribute to abnormal cell survival and migration in breast tumors that lack functional p53 protein. Another study has indicated that prostate cancer tissue as well as cell lines express higher non-basal levels of CXCR5 and found a correlation between the level of CXCR5 and Gleason score. CXCR5 location was additionally considered and higher Gleason scores correlated with nuclear CXCR5 while cytoplasmic and membrane CXCR5 correlated with benign and early prostate cancers.